Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

Celldex Therapeutics initiates CDX-1127 Phase 1 study in malignant solid tumors

Celldex Therapeutics, Inc. today announced initiation of a Phase 1 study of its therapeutic human antibody candidate, CDX-1127, in patients with selected malignant solid tumors or hematologic cancers.

8 Nov 2011

TWIST protein plays a major role in controlling estrogen resistance in breast cancer

In dozens of experiments in mice and in human cancer cells, a team of Johns Hopkins scientists has closely tied production of a cancer-causing protein called TWIST to the development of estrogen resistance in women with breast cancer.

8 Nov 2011

Survey shows low awareness for non-surgical permanent birth control methods

A recent first-of-its-kind survey of 1,006 mothers in the U.S. showed that more than 75 percent of women reported being done having children, but only 24 percent discussed this decision with their OB/GYNs.

8 Nov 2011

Connexin 36 protects mouse pancreatic beta-cells against immune molecules

Type 1 diabetes is a lifelong disease characterized by high levels of sugar (glucose) in the blood. It is caused by the patient's immune system attacking and destroying the cells in their pancreas that produce the hormone insulin, which regulates blood glucose levels. Surprisingly, little is known about the mechanisms regulating the sensitivity and resistance of these cells, which are known as beta-cells, to immune system attack.

7 Nov 2011

Brain plays a key role in regulating glucose metabolism in humans

Researchers at Albert Einstein College of Medicine of Yeshiva University have demonstrated for the first time that the brain is a key player in regulating glucose (sugar) metabolism in humans.

7 Nov 2011

DuoCort Pharma granted marketing authorization for adrenal insufficiency drug, Plenadren in Europe

The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years.

7 Nov 2011

Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announced positive top-line results from REPLACE, a Phase 3 registration study of NPSP558, the company's bioengineered replica of human parathyroid hormone (rhPTH 1-84), in adult hypoparathyroidism patients.

7 Nov 2011

Exposure to air pollution may increase risk of RA

Exposure to some types of air pollution, especially sulfur dioxide — one of the six most common pollutants in the United States — is associated with a somewhat increased risk of developing rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Psychological stress can trigger flares of vasculitis

In patients with a devastating form of vasculitis who are in remission, stress can be associated with a greater likelihood of the disease flaring, according to a new study by investigators at Hospital for Special Surgery.

6 Nov 2011

Sitting around could be waiting for cancer to strike say researchers

A new analysis reveals that more than 90,000 new cancer cases a year in the United States may be due to physical inactivity and prolonged periods of sitting. The researchers presented their findings at the annual conference of the American Institute for Cancer Research (AICR) in Washington, D.C., citing about 49,000 cases of breast cancer and 43,000 of colon cancer from over 200 studies worldwide.

6 Nov 2011

GTx third quarter net loss increases to $9.3 million

GTx, Inc. today reported financial results for the third quarter of 2011. The net loss for the quarter ended September 30, 2011 was $9.3 million compared with a net loss of $8.6 million for the quarter ended September 30, 2010, reflecting increased research and development costs in connection with the Company's Ostarine™ and Capesaris™ clinical development programs.

4 Nov 2011

New way to screen hirsutism among women

Examining the chin and upper and lower abdomen is a reliable, minimally invasive way to screen for excessive hair growth in women, a key indicator of too much male hormone, researchers report.

4 Nov 2011

Exendin-4 drug could prevent later development of diabetes in children

Pediatric researchers who tested newborn animals with an existing human drug used in adults with diabetes report that this drug, when given very early in life, prevents diabetes from developing in adult animals. If this finding can be repeated in humans, it may become a way to prevent at-risk infants from developing type 2 diabetes.

3 Nov 2011

Scientists discover how to starve prostate cancer cells

Each year about 3300 Australian men die of prostate cancer. It's Australia's second worst cancer killer for men, matching the impact of breast cancer on women. Current therapies for prostate cancer include surgical removal of the prostate, radiation, freezing the tumour or cutting off the supply of the hormone testosterone-but there are often side-effects including incontinence and impotence.

3 Nov 2011

Benefits of combined therapy for men with high-risk prostate cancer

Men with locally advanced or high-risk prostate cancer who receive combined radiation and hormone therapy live longer and are less likely to die from their disease, shows clinical research led by radiation oncologists at the Princess Margaret Hospital (PMH) Cancer Program, University Health Network.

3 Nov 2011

Researchers use diabetes drug to permanently reprogram insulin-producing cells

3 Nov 2011

Study reveals new role for the 'hormone of love'

Much of the body's chemistry is controlled by the brain - from blood pressure to appetite to food metabolism. In a study published recently in Developmental Cell, a team of scientists led by Dr. Gil Levkowitz of the Weizmann Institute has revealed the exact structure of one crucial brain area in which biochemical commands are passed from the brain cells to the bloodstream and from there to the body. In the process, they discovered a surprising new role for the 'hormone of love,' showing that it helps to direct the development of this brain structure.

3 Nov 2011

Isis commences ISIS-GCGRRx and ISIS-GCCRRx Phase 1 studies for type 2 diabetes

Isis Pharmaceuticals, Inc. announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes.

2 Nov 2011

Inhibiting Notch signalling makes hormone-receptor positive cells dependent on estrogen

Within many hormone-receptor positive breast cancers lives a subpopulation of receptor-negative cells - knock down the hormone-receptor positive cells with anti-estrogen drugs and you may inadvertently promote tumor takeover by more dangerous, receptor-negative cells.

2 Nov 2011

First study to evaluate mycoestrogens in young girls

Puberty is a time in a girl's life considered highly sensitive to stimulation by the hormone estrogen and a critical window during which estrogen exposure could greatly influence the risk of breast cancer later in life. An early onset of puberty also has been consistently shown in studies to increase the risk of breast cancer.

2 Nov 2011